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Background: Parkinson disease is a neurodegenerative disease that affects gait and postural stability, resulting in an
increased risk of falling. The purpose of this study was to estimate mortality associated with demographic factors after hip
or pelvic (hip/pelvic) fracture in people with Parkinson disease. A secondary goal was to compare themortality associated
with Parkinson disease to that associated with other common medical conditions in patients with hip/pelvic fracture.
Methods: This was a retrospective observational cohort study of 1,980,401 elderly Medicare beneficiaries diagnosed
with hip/pelvic fracture from 2000 to 2005who were identified with use of the Beneficiary Annual Summary File. The race/
ethnicity distribution of the sample was white (93.2%), black (3.8%), Hispanic (1.2%), and Asian (0.6%). Individuals with
Parkinson disease (131,215) were identified with use of outpatient and carrier claims. Cox proportional hazards models
were used to estimate the risk of death associated with demographic and clinical variables and to compare mortality after
hip/pelvic fracture between patients with Parkinson disease and those with other medical conditions associated with high
mortality after hip/pelvic fracture, after adjustment for race/ethnicity, sex, age, and modified Charlson comorbidity score.
Results: Among those with Parkinson disease, women had lower mortality after hip/pelvic fracture than men (adjusted
hazard ratio [HR]= 0.63, 95% confidence interval [CI])= 0.62 to 0.64), after adjustment for covariates. Comparedwith whites,
blacks had a higher (HR = 1.12, 95% CI = 1.09 to 1.16) and Hispanics had a lower (HR = 0.87, 95% CI = 0.81 to 0.95)
mortality, after adjustment for covariates. Overall, the adjusted mortality rate after hip/pelvic fracture in individuals with
Parkinson disease (HR= 2.41, 95%CI= 2.37 to 2.46) was substantially elevated compared with thosewithout the disease, a
finding similar to the increasedmortality associated with a diagnosis of dementia (HR = 2.73, 95% CI = 2.68 to 2.79), kidney
disease (HR = 2.66, 95% CI = 2.60 to 2.72), and chronic obstructive pulmonary disease (HR = 2.48, 95% CI = 2.43 to 2.53).
Conclusions: Mortality after hip/pelvic fracture in Parkinson disease varies according to demographic factors. Mortality
after hip/pelvic fracture is substantially increased among those with Parkinson disease.
Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
P
arkinson disease is a neurodegenerative disease char-
acterized by bradykinesia, rigidity, resting tremor, and
postural instability1. With disease progression, postural
instability increases, often leading to falls2,3. While dopaminergic
therapy improves tremor and rigidity, symptoms such as bra-
dykinesia, freezing when walking, and impaired balance may
remain, resulting in an increased risk of falls and injury4,5. People
with Parkinson disease are particularly susceptible to hip frac-
tures5-7, with a 3.2-fold greater risk compared with the risk for
people without Parkinson disease8. In addition to gait distur-
bances and postural instability, other factors such as postural
hypotension, decreased bone mineral density9,10, low vitamin-D
levels11,12, dementia8, medications5, and advanced age8 further in-
crease the fracture risk for people with Parkinson disease.
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Among the general population, mortality rates for people
with hip fractures are reported to be up to 36% greater com-
pared with the rates in non-hip-fracture reference popula-
tions13. Although it is clear that hip fracture increases mortality
in the general population, less is known about the mortality
risk after hip fracture in people with Parkinson disease. Hip
fractures are common in Parkinson disease and recovery may
be complicated by the disease signs and symptoms. Under-
standing the comparative mortality associated with hip fracture
in patients with and without Parkinson disease may help
identify those at higher risk of death and determine specific
treatment strategies to reduce that risk.
The goal of this study was to investigate mortality rates
associated with demographic and clinical risk factors after hip or
pelvic (hip/pelvic) fractures in people with Parkinson disease and
compare these rates with postfracture mortality rates among
those with other medical conditions. We hypothesized that,
similar to what has been found in non-Parkinson disease popu-
lations,menwithParkinsondiseasewouldhave ahighermortality
after hip/pelvic fracture than womenwith Parkinson disease, and
thatmortality would differ according to race/ethnicity. Finally, we
expected patients with Parkinson disease to have greatermortality
after hip/pelvic fracture than those without Parkinson disease.
Materials and Methods
This study was approved by the Human Protection Research Office of theWashington University School of Medicine.
Study Population
Beneficiaries with a Medicare part-A or B claim for a hip fracture from 2000 to
2005 were identified from theMedicare Beneficiary Annual Summary File, which
contains the date of diagnosis of a hip fracture. In theMedicare Beneficiary Annual
Summary File, the diagnosis of hip fracture (hereafter referred to as ‘‘hip/pelvic
fracture’’) includes any fracture of the proximal part of the femur, acetabulum, or
pelvic ring. The International Classification of Diseases, Ninth Revision (ICD-9)
codes representing the hip fracture diagnosis in the Medicare Beneficiary Annual
Summary File are provided in the Appendix of this article. The Medicare Bene-
ficiary Annual Summary File also contains twenty-one other common diseases
contained in Medicare’s Chronic Condition Data Warehouse, as well as demo-
graphic and vital status data
14
. Using these data, we identified hip/pelvic fracture
cases with the following comorbid diagnoses: chronic obstructive pulmonary
disease, stroke/transient ischemic attack, diabetes mellitus, ischemic heart disease,
osteoporosis, dementia, heart failure, and chronic kidney disease. Medicare out-
patient and carrier claims data were used to identify hip/pelvic fracture cases with
comorbid Parkinson disease with use of previously published methods
15,16
.
Demographic and Clinical Data
Race/ethnicity (according to standardMedicare race codes), sex, and date of birth
were extracted for each subject. Using information from Medicare’s Chronic
Condition Data Warehouse contained in the Medicare Beneficiary Annual
Summary File, we calculated an age-weighted modified Charlson comorbidity
score for each case on the basis of the presence of malignant disease (breast,
prostate, endometrial, lung, or colon/rectum), ischemic heart disease, diabetes,
chronic obstructive pulmonary disease, stroke/transient ischemic attack, acute
myocardial infarction, chronic kidney disease, or heart failure
14
. Using specifi-
cations documented by Medicare’s Chronic Condition Data Warehouse
17
, we
calculated the Charlson comorbidity score on the basis of the presence of a
diagnostic claim made in any inpatient or outpatient setting. The time frames
used by the Chronic Condition Data Warehouse are (1) the previous calendar
year for malignant disease, chronic obstructive pulmonary disease, stroke/tran-
sient ischemic attack, and acute myocardial infarction and (2) the previous two
years for ischemic heart disease, diabetes, chronic kidney disease, or heart failure.
Survival Analyses
Survival status was determined by using the 2000 to 2008 Medicare Beneficiary
Annual Summary Files with previously published methods
18
. The time-to-
event variable was calculated from the date of the hip/pelvic fracture to the
recorded date of death (measured in months). Surviving cases were censored
at the end of the calendar year in 2008. Covariates included race, sex, age at
diagnosis, and modified Charlson comorbidity score. To investigate whether
demographic or clinical factors were associated with differential survival after
hip/pelvic fracture in people with Parkinson disease, we performed Cox pro-
portional hazard analysis using people with Parkinson disease and hip/pelvic
fracture and adjusting for age and modified Charlson comorbidity score. To in-
vestigate comparative mortality, we performed Cox proportional hazards analysis
comparingmortality of people with Parkinson disease and hip/pelvic fracture with
TABLE I Demographic Characteristics
Patient Characteristics
Parkinson Disease with Hip
Fracture (N = 131,215)
No Parkinson Disease with Hip
Fracture (N = 1,849,186)
All with Hip Fracture
(N = 1,980,401)
Race/ethnicity* (no. [%])
White 123,769 (94.3) 1,722,622 (93.2) 1,846,391 (93.2)
Black 3632 (2.8) 71,553 (3.9) 75,185 (3.8)
Hispanic 1829 (1.4) 22,087 (1.2) 23,916 (1.2)
Asian 787 (0.6) 11,270 (0.6) 12,057 (0.6)
Sex (no. [%])
Male 45,563 (34.7) 423,355 (22.9) 468,918 (23.7)
Female 85,652 (65.3) 1,426,831 (77.2) 1,512,483 (76.4)
Mean age (standard deviation) (yr) 81.0 (7.8) 82.3 (6.6) 82.2 (7.7)
Mean modified Charlson comorbidity
score (standard deviation)
6.47 (1.72) 6.30 (1.84) 6.33 (1.84)
*Native American, unknown, and other were not reported due to small numbers of subjects or race ambiguity; therefore percentages do not
equal 100.
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mortality of people with hip/pelvic fracture and other common illnesses (de-
mentia, stroke, chronic obstructive pulmonary disease, kidney disease, diabetes,
heart failure, ischemic heart disease, and osteoporosis), with hip/pelvic fracture
cases without any of these conditions used as the reference group.
Statistical Analyses
Descriptive analyses were performed to compare members of the study popu-
lation by survival status according to demographic and clinical variables. We
used independent t tests to comparemeans of continuous variables, and we used
chi-square tests to compare proportions. Standard methods were used to pro-
duce Cox proportional hazard coefficients with 95% confidence intervals (CIs).
Source of Funding
Funding for this study was received from the National Institute of Neurological
Disorders and Stroke (5T32NS007205-27); National Center for Research Re-
sources and National Institutes of Health Roadmap for Medical Research
(UL1RR024992, KL2RR024994); National Institute of Environmental Health
Sciences (K24 ES017765); National Institute of Child Health and Human De-
velopment, National Center forMedical Rehabilitation Research (K23HD67343);
St. Louis chapter of the American Parkinson Disease Association; Walter and
Connie Donius; and the Robert Renschen Fund.
Results
Subject Demographics
The demographic characteristics of the study population aresummarized in Table I. Our analysis included 1,980,401
individuals who had sustained a hip/pelvic fracture, 131,215 of
whom had Parkinson disease. There weremore whites and fewer
blacks in the Parkinson disease cohort than in the general hip/
pelvic fracture population (p < 0.001).While in both groups, the
majority of the patients with a fracture were women, 34.7%
of the patients with a hip/pelvic fracture and Parkinson disease
were men compared with 22.9% of the individuals with a hip/
pelvic fracture who did not have Parkinson disease (p < 0.001).
Those with Parkinson disease were younger and demonstrated a
higher modified Charlson comorbidity score than those without
Parkinson disease (p < 0.001).
Association of Mortality with Sex, Race/Ethnicity
The risk of death after hip/pelvic fracture associated with sex
and race/ethnicity among beneficiaries with Parkinson disease
are provided in Table II. After adjustments for age, race, and
modified Charlson comorbidity score, women had a lower risk
of death than men (adjusted hazard ratio [HR] = 0.63, 95%
CI = 0.62 to 0.64). Compared with whites with Parkinson disease,
blacks with Parkinson disease had higher mortality (adjusted
HR = 1.12, 95% CI = 1.09 to 1.16) and Hispanics with Par-
kinson disease had lower mortality (adjusted HR = 0.87, 95%
CI = 0.81 to 0.95). The mortality rates of whites and Asians
were similar (adjusted HR = 0.93, 95% CI = 0.85 to 1.02).
Association of Mortality with Medical Condition
The risks of death after hip/pelvic fracture associated with
Parkinson disease and other medical conditions are provided in
Table III. Among all individuals with hip/pelvic fracture, those
with Parkinson disease had a greater risk of death (adjusted
TABLE II Post-Hip Fracture Mortality Risk Associated with Sex and Race/Ethnicity Among Individuals with Parkinson Disease
Unadjusted Adjusted*
HR 95% CI HR 95% CI P Value
Race/ethnicity
White Reference Reference
Black 1.00 0.97-1.04 1.12 1.09-1.16 <0.001
Hispanic 0.86 0.81-0.91 0.87 0.81-0.95 0.001
Asian 0.78 0.72-0.85 0.93 0.85-1.02 0.132
Sex
Male Reference Reference
Female 0.65 0.64-0.66 0.63 0.62-0.64 <0.001
*Adjusted for age and age-weighted modified Charlson comorbidity score, with the race/ethnicity analysis adjusted for sex as well and the sex
analysis adjusted for race/ethnicity as well.
TABLE III Post-Hip Fracture Mortality Risk Associated with
Medical Conditions*
HR* 95% CI P Value
No documented disease Reference
Dementia 2.73 2.68-2.79 <0.001




Parkinson disease 2.41 2.37-2.46 <0.001




Heart failure 2.28 2.23-2.33 <0.001
Ischemic heart disease 2.17 2.14-2.21 <0.001
Osteoporosis 1.89 1.86-1.92 <0.001
*Adjusted for age, age-weighted modified Charlson comorbidity
score, sex, and race/ethnicity.
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HR = 2.41, 95% CI = 2.37 to 2.46) than patients without
Parkinson disease. Patients with dementia (adjusted HR = 2.73,
95% CI = 2.68 to 2.79), kidney disease (adjusted HR = 2.66,
95% CI = 2.60 to 2.72), or chronic obstructive pulmonary
disease (adjusted HR = 2.48, 95% CI = 2.43 to 2.53) had the
highest mortality.
Discussion
Despite hip fractures being common in individuals withParkinson disease5-7, little is known about the factors as-
sociated with the post-hip fracture mortality of these individ-
uals. Similar to what has been found in the general population,
men with Parkinson disease demonstrated a higher risk of
death than women. We also found that mortality varied across
race/ethnic categories, with black patients demonstrating a
higher and Hispanic patients demonstrating a lower adjusted
risk of death compared with white patients. Finally, we dem-
onstrated that people with Parkinson disease had substantially
increased postfracture mortality, suggesting a need for aggressive
fracture prevention and coordinated postfracture care for people
with Parkinson disease.
A major strength of our study is the large sample size. The
sample was obtained with use of the Medicare data set, the only
population-based U.S. health-care database, which provides
substantial power to detect effects on mortality. We were able to
achieve complete case follow-up and adjust for multiple factors,
including comorbidities. Additionally, we were able to deter-
mine mortality differences based on race/ethnicity, which is
often underreported in studies of hip fracture. Finally, Medicare
data provide a ‘‘real world’’ demonstration of the impact of hip/
pelvic fracture on patients with Parkinson disease, in contrast to
specialty center studies that report outcomes on a select and
often non-representative population. Our study demonstrates
the importance of demographic factors in mortality after hip/
pelvic fracture in people with Parkinson disease.
Our findings related to sex are consistent with those of
previous studies on mortality following hip fracture in the
general population19-28. A meta-analysis of mortality following
hip fracture surgery demonstrated that men with hip fracture
have a higher mortality (pooled HR = of 1.7) than women27.
The relationship was similar among those with Parkinson
disease in our study. It is unclear why men have higher mor-
tality after fracture than women. Previous studies have indi-
cated that men have more comorbidities and more severe
comorbidities at the time of fracture19,20,22-24, but male sex re-
mained a significant risk factor after adjustment for comor-
bidities in our study and in others19,20,22-24. We were unable to
adjust for comorbidity severity, postural instability, gait im-
pairments, or postoperative complications due to the limited
data available in this administrative data set.
We are the first, to our knowledge, to report on the as-
sociation between race/ethnicity and mortality after hip/pelvic
fracture in people with Parkinson disease. Studies related to
race/ethnicity and mortality after hip/pelvic fracture in the
general population have shown conflicting results. Jacobsen
et al.28 used Medicare data from 1984 to 1987 to assess the
relationship between sex/race pairings and mortality and re-
ported that mortality rates among white and black men were
similar, but black women had a higher mortality rate (22.9 of
1000) than white women (17.2 of 1000). Lu-Yao et al.21 used
Medicare data from 1986 to 1989 and reported that, compared
with whites, blacks (adjusted odds ratio [OR] = 1.21, 95% CI =
1.08 to 1.36) and patients with other, unknown, or missing
race (adjusted OR = 1.65, 95% CI = 1.41 to 1.94) had higher
mortality. Penrod et al.29 also found that whites were more likely
to survive (adjusted OR = 1.74, 95% CI = 1.15 to 2.65) after hip
fracture compared with nonwhites. Hannan et al.30 reported
greater six-month mortality in nonwhite patients (24%) com-
pared withwhite patients (13%); however, this difference was not
significant. In contrast, Orces and Alamgir31 reported higher
post-hip fracture mortality in whites compared with blacks and
Hispanics among people aged fifty years and older. Our study
showed disproportionatemortality among blacks with hip/pelvic
fractures and emphasizes the importance of identifying con-
tributors such as health-care quality (both Parkinson disease-
related and general) and access to and utilization of specialty care.
The reduced mortality found among Hispanics in our
data set, however, suggests that socioeconomic factors may not
be the only consideration when assessing differences related to
race/ethnicity. Our findings are consistent with previous studies
that have shown similar differences related to race/ethnicity in
all-cause mortality32. Compared with whites, blacks demonstrate
higher and Hispanics demonstrate lower all-cause mortality32.
Socioeconomic differences have been implicated in the higher
all-cause mortality among blacks32; however, socioeconomic
differences may not explain the lower mortality in Hispanics.
Hispanics in the U.S. demonstrate lower all-cause mortality
compared with non-Hispanics despite lower socioeconomic
status and lower rate of health insurance coverage33,34. Three
theories to explain this paradox include (1) migration patterns
that involve healthier people emigrating to the U.S. and less
healthy people returning to their native country; (2) positive
cultural differences, such as diet or family structure; and (3)
potential data artifacts. Investigators have also found that this
may be a feature specific to certainHispanic subgroups related to
national origin or ancestry34,35. We cannot address migration
patterns or cultural differences on the basis of the administrative
data used in our study.
We found increased mortality associated with Parkinson
disease similar to that associated with other conditions, such as
dementia, kidney disease, chronic obstructive pulmonary dis-
ease, and diabetes. Previous reports specific to Parkinson dis-
ease and hip fracture have revealed conflicting findings. Studies
published in 1980 and 1990 showed increased mortality fol-
lowing hip fracture in patients with Parkinson disease36,37.
These early studies, however, included patients without access
to therapies such as deep brain stimulation or aggressive re-
habilitation protocols that are in current use. Three recently
published studies demonstrated no relationship between Par-
kinson disease andmortality after hip fracture25,29,38. However, all
were based on relatively small samples, the largest being 2692
subjects29. In contrast, our study includes data from 1,980,401
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Medicare beneficiaries diagnosed with hip/pelvic fracture,
representing the entire elderly hip/pelvic fracture population in
the U.S.
Our findings suggest that treatment strategies to prevent
hip/pelvic fracture and reduce mortality after fracture, partic-
ularly in menwith Parkinson disease, have the potential to have
a substantial public health impact. Most studies have investi-
gated the prevention and treatment of hip fractures in women
because of their higher risk for sustaining a hip fracture. Even
though women are more likely to sustain a fracture, men are
more likely to die after the fracture. Therefore preventative
screenings and treatment strategies targeting those at risk for
falls and subsequent hip fracture should not be limited to
women25 as they could be potentially life-saving for men. One
example is screening for osteoporosis, a risk factor for hip
fracture. A statement recently published by the U.S. Preventive
Services Task Force provided specific recommendations for
osteoporosis screening for women but did not provide a rec-
ommendation for men because of insufficient evidence. Given
the lack of evidence to support osteoporosis screening for men,
it is likely that osteoporosis is underdiagnosed in men. This
may be particularly true for men with Parkinson disease, who
are more likely to have low bone mineral density compared
with healthy controls9,39. In their study of 177 patients newly
diagnosed with Parkinson disease, Eng et al.40 reported that
only 11% of men had been previously screened for low bone
mineral density compared with 71% of women. Evaluation
provided by a physical therapist may also assist in preventing
hip/pelvic fracture by identifying, through gait and balance
analysis, patients with Parkinson disease who are at risk for
falls41,42 and by providing treatment to improve gait and pos-
tural instability, thus reducing the risk of falls43-45.
Coordinated care during the perioperative phase may
also help to reduce postfracture mortality of patients with Par-
kinson disease. Hip/pelvic fracture and the subsequent hospi-
talization can interrupt complex Parkinson disease medication
regimens, reduce efficacy of Parkinson disease medications, and
result in a decline in functional mobility46-49. Recent reports
highlight the clinical problems faced by patients with Parkinson
disease when hospitalized, such as frequent medication errors,
infections, confusion, falls, and decubitus ulcers46-49. An inter-
disciplinary team that is educated in the complexities of Par-
kinson disease management likely improves outcomes49. A small
retrospective study of patients with Parkinson disease who un-
derwent a total knee arthroplasty showed that early involvement
of a neurologist in the postoperative phase resulted in signifi-
cantly shorter hospital stays and improved early outcomes50,
suggesting the need for early neurologic consultation to reduce
associated morbidities.
Our study had limitations. There are a number of factors
proposed to be related to mortality after hip/pelvic fracture for
which we could not account, including prefracture residence27,
previous level of function27, smoking25, fracture type30,51, and type
of postfracture management. These variables are not contained
in the Medicare database52. There was also no way to track
Parkinson disease or comorbidity severity, which likely remain
important uncontrolled confounders. We were not able to val-
idate the accuracy of the diagnosis of Parkinson disease, so
conditions mimicking Parkinson disease such asmultiple system
atrophy may have been misdiagnosed as Parkinson disease and
could have influenced the results. However, atypical parkinsonism
represent only a small percentage of the total cases presenting with
parkinsonism53,54. Minority representation in our data set is lower
than that of the U.S. population55. The difference in minority
representation in our data set, however, is likely influenced by
selection of only Medicare beneficiaries who had sustained a
hip/pelvic fracture. Whites are more likely to sustain a hip/
pelvic fracture than minority populations56,57, which may ex-
plain the discrepancy. The hip fracture variable provided in the
Medicare Beneficiary Annual Summary File includes all hip
and pelvic fractures that the Centers for Medicare & Medicaid
Services (CMS) determined to be relevant to classify as hip
fractures. We were unable to identify fracture subtypes, post-
fracture management, operative procedure, or nonoperative
approach provided for each patient. The goal of our current
study, however, was to assess the mortality associated with any
hip/pelvic fracture in patients with Parkinson disease, a pop-
ulation prone to immobility due to the neurodegenerative
disease. Moreover, the inclusion of pelvic fractures, which have
lower associated mortality58,59, likely resulted in an underesti-
mate of the true mortality associated with femoral and inter-
trochanteric fractures in patients with Parkinson disease.
Postural instability in Parkinson disease is associated with an
increased risk of falls, and, although the distribution of ana-
tomical site cannot be determined from these data, high-energy
fractures may be more likely in people with Parkinson disease.
The increased mortality that we observed may reflect a greater
percentage of high-energy fractures or a greater tendency to-
ward high-energy fractures.
Despite these limitations, our study provides valuable in-
formation on the relative mortality of people with Parkinson
disease and hip/pelvic fracture. The risk of death after hip/pelvic
fracture in people with Parkinson disease varies according to
demographic factors. Mortality is increased substantially after
hip/pelvic fracture amongpatientswithParkinsondisease. Future
studies to understand the factors that contribute to increased
mortality after hip/pelvic fracture in patients with Parkinson
disease and in subpopulations will help guide treatment strategies
to reduce morbidity and mortality in these complex cases.
Appendix
A table showing ICD-9 codes representing the hip frac-
ture diagnosis in the Medicare Beneficiary Annual Sum-
mary File is available with the online version of this article as a
data supplement at jbjs.org. n
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